would
difficult
exagger
import
exacerb
patient
chronic
obstruct
pulmonari
diseas
copd
copd
fifth
lead
caus
death
worldwid
mortal
morbid
often
associ
episod
symptom
deterior
term
exacerb
furthermor
wherea
death
rate
preval
condit
fall
mortal
copd
continu
rise
exacerb
copd
account
emerg
medic
admiss
hospit
inhospit
mortal
exacerb
consequ
respons
direct
cost
attribut
copd
exacerb
gener
becom
frequent
sever
sever
underli
copd
progress
averag
patient
moder
sever
copd
typic
attend
secondari
care
one
two
exacerb
requir
addit
treatment
annual
howev
annual
exacerb
incid
rate
differ
greatli
among
individu
patient
prone
frequent
exacerb
experi
particular
burden
diseas
figur
best
determin
futur
exacerb
histori
past
exacerb
frequenc
patient
appear
intrins
suscept
resist
import
event
world
health
organ
defin
copd
diseas
state
pulmonari
compon
character
airflow
limit
progress
fulli
revers
associ
abnorm
inflammatori
respons
noxiou
particl
gase
airway
inflamm
even
greater
exacerb
assumpt
addit
inflamm
provok
symptom
worsen
dyspnea
sputum
product
mechan
relat
airway
tone
airway
wall
edema
mucu
product
result
air
trap
increas
work
breath
caus
addit
impair
respiratori
muscl
function
trigger
increas
airway
inflamm
therefor
caus
exacerb
predominantli
tracheobronchi
infect
lesser
role
pollut
howev
effect
increas
inflamm
exacerb
requir
clarif
direct
relationship
clinic
sever
exacerb
degre
airway
inflamm
never
conclus
demonstr
defin
role
airway
infect
caus
copd
exacerb
problemat
recent
advanc
molecular
biolog
isol
respiratori
virus
potenti
pathogen
bacteria
airway
patient
exacerb
box
howev
certainli
patient
sever
underli
diseas
bacteria
also
often
present
stabl
state
bacteri
colon
therefor
presenc
organ
exacerb
assum
role
caus
exacerb
recent
studi
suggest
chang
colon
bacteri
strain
may
precipit
caus
howev
strain
chang
associ
exacerb
vice
versa
reflect
discuss
later
antibiot
univers
benefit
exacerb
rhinoviru
often
identifi
viral
pathogen
thu
exacerb
common
winter
month
viral
circul
commun
higher
role
atyp
organ
chlamydia
mycoplasma
speci
appear
minim
regard
pollut
caus
copd
exacerb
larg
epidemiolog
studi
link
rise
pollut
level
increas
hospit
admiss
respiratori
diseas
particul
matter
less
size
pm
appear
particularli
import
pollut
microorgan
may
interact
amplifi
risk
exacerb
copd
patient
seem
suscept
exacerb
may
genet
determin
exacerb
frequenc
support
suscept
exacerb
famili
compon
singl
polymorph
yet
report
explain
varianc
exacerb
frequenc
observ
copd
patient
recogn
copd
associ
upregul
system
inflamm
ampl
evid
demonstr
heighten
system
inflamm
exacerb
may
import
given
associ
cardiovascular
death
elev
system
inflammatori
marker
mani
patient
copd
die
cardiovascular
diseas
system
inflamm
thought
repres
spillov
lung
understand
pathophysiolog
exacerb
copd
explain
rational
variou
therapi
employ
bronchodil
may
help
increas
bronchoconstrict
hyperinfl
corticosteroid
may
reduc
airway
inflamm
antibiot
may
appropri
exacerb
caus
bacteria
figur
cardin
featur
copd
exacerb
increas
respiratori
symptom
beyond
usual
patient
john
r
hurst
l
jadwiga
wedzicha
exacerb
heterogen
event
clinic
featur
vari
wide
may
best
consid
sever
present
repres
combin
sever
underli
copd
exacerb
patient
mild
underli
diseas
may
experi
troublesom
worsen
symptom
wherea
sever
copd
signific
risk
respiratori
failur
furthermor
condit
occur
patient
underli
copd
may
mimic
complic
exacerb
proper
assess
describ
next
therefor
import
exacerb
copd
clinic
syndrom
confirmatori
diagnost
test
although
controversi
surround
exactli
defin
exacerb
differ
import
interpret
studi
result
wide
accept
exacerb
sustain
worsen
patient
symptom
acut
onset
beyond
daytoday
variat
may
necessit
chang
therapi
although
investig
help
diagnosi
exacerb
diagnost
test
help
assess
sever
present
exclud
condit
patient
underli
copd
may
mimic
complic
exacerb
diagnos
includ
pneumonia
pneumothorax
pulmonari
embolu
cardiac
failur
appropri
investig
includ
chest
radiographi
electrocardiographi
oxygen
satur
sao
valu
arteri
blood
ga
abg
analysi
simpl
venou
blood
test
includ
complet
blood
count
urea
electrolyt
creactiv
protein
typic
chest
radiograph
exacerb
figur
appear
much
patient
radiograph
stabl
state
spirometri
gener
help
absolut
valu
may
mislead
chang
exacerb
small
patient
acut
dyspneic
difficulti
perform
maneuv
sputum
microscopi
cultur
may
help
refin
empir
antibiot
therapi
initi
improv
patient
mild
exacerb
respond
increas
inhal
bronchodil
may
appropri
omit
investig
typic
symptom
includ
dyspnea
sputum
volum
sputum
purul
cough
wheez
perhap
accompani
upper
respiratori
tract
symptom
rhinorrhea
clinic
sign
nonspecif
may
includ
tachycardia
tachypnea
cyanosi
use
accessori
respiratori
muscl
polyphon
expiratori
wheez
crackl
auscult
featur
carbon
dioxid
retent
cor
pulmonal
higher
mortal
faster
declin
lung
function
poorer
qualiti
life
patient
prescrib
longact
bronchodil
normal
continu
therapi
evid
minim
support
introduct
longact
agent
exacerb
therapi
shortact
drug
prefer
recommend
approach
therefor
increas
dose
frequenc
either
shortact
agonist
anticholinerg
drug
use
togeth
event
inadequ
clinic
respons
system
corticosteroid
indic
copd
exacerb
except
milder
event
respond
increas
inhal
bronchodil
alon
number
random
trial
summar
systemat
review
demonstr
rapid
improv
fev
administr
steroid
although
effect
outcom
oxygen
hospit
length
stay
variabl
definit
evid
mortal
benefit
guidelin
vari
specif
recommend
gener
suggest
oral
prednison
mg
day
prolong
cours
provid
addit
benefit
increas
risk
side
effect
evid
suggest
taper
dose
advantag
physician
choos
give
first
dose
prednison
intraven
nebul
budesonid
result
similar
improv
lung
function
oral
dose
expens
prednison
intriguingli
use
system
steroid
may
delay
time
subsequ
exacerb
although
initi
inhal
steroid
role
exacerb
inhal
corticosteroid
import
role
exacerb
prevent
discuss
later
anthonisen
semin
work
antibiot
copd
exacerb
demonstr
benefit
patient
increas
least
two
three
symptom
breathless
sputum
volum
sputum
purul
sputum
purul
reliabl
indic
presenc
bacteria
exacerb
recent
metaanalysi
confirm
small
statist
signific
benefit
favor
antibiot
local
resist
pattern
antibiot
polici
dictat
choic
drug
coverag
includ
common
pathogen
haemophilu
influenza
moraxella
branhamella
catarrhali
streptococcu
pneumonia
oral
aminopenicillin
macrolid
tetracyclin
therefor
appropri
empir
choic
compar
data
across
drug
class
spars
intraven
antibiot
rare
requir
data
optim
durat
therapi
minim
antibiot
use
exacerb
may
also
prolong
time
subsequ
exacerb
perhap
modul
airway
bacteri
load
oxygen
indic
correct
hypoxem
respiratori
failur
may
result
copd
exacerb
treatment
breathless
hypoxemia
caus
combin
increas
ventilationperfus
vq
mismatch
alveolar
hypoventil
oxygen
administ
control
manner
monitor
abg
tension
avoid
carbon
dioxid
co
retent
develop
hypercapn
respiratori
failur
may
occur
proport
patient
classic
said
reli
hypox
respiratori
drive
studi
shown
littl
risk
hypercapnia
oxygen
titrat
maximum
satur
failur
correct
hypoxemia
fraction
inspir
oxygen
fio
suggest
presenc
addit
accept
method
assess
exacerb
sever
repres
combin
sever
underli
diseas
exacerb
insult
quantifi
chang
symptom
lung
function
requir
knowledg
patient
baselin
difficult
achiev
gener
help
consequ
degre
health
care
util
use
surrog
assess
sever
mild
exacerb
requir
increas
inhal
bronchodil
moder
exacerb
requir
antibiot
corticosteroid
commun
patient
sever
exacerb
requir
hospit
admiss
ph
best
indic
acut
chang
alveolar
ventil
exacerb
associ
respiratori
failur
requir
hospit
assess
howev
decis
admit
patient
depend
sever
exacerb
would
includ
exampl
social
circumst
support
avail
patient
home
principl
therapi
time
copd
exacerb
twofold
modifi
cours
event
support
patient
respiratori
function
diseasemodifi
therapi
work
treatment
given
proport
clinic
sever
event
sequenti
approach
illustr
figur
mani
guidelin
exist
guid
appropri
therapi
includ
recent
updat
evidencebas
statement
uk
nation
institut
clinic
excel
nice
attent
comorbid
also
import
recoveri
phase
clinician
consid
intervent
may
reduc
risk
subsequ
exacerb
increas
dose
frequenc
inhal
shortact
bronchodil
mainstay
copd
exacerb
therapi
bronchodil
effect
similar
agonist
albuterol
salbutamol
anticholinerg
drug
ipratropium
bromid
although
often
use
combin
littl
evid
suggest
addit
benefit
also
evid
indic
nebul
effect
administ
drug
inhal
largevolum
spacer
howev
nebul
often
prefer
dyspneic
patient
may
less
demand
nurs
time
nebul
copd
driven
compress
air
increas
sever
exacerb
set
niv
may
valuabl
aim
ventil
support
ga
exchang
respiratori
muscl
function
therapi
suffici
time
effect
circumst
parenter
corticosteroid
antibiot
usual
given
bronchodil
may
ad
ventil
circuit
inhal
spacer
methylxanthin
drug
theophyllin
varieti
potenti
benefici
effect
respiratori
cardiac
function
metaanalysi
fail
show
benefit
lung
function
symptom
methylxanthin
copd
exacerb
despit
wellrecogn
problem
drug
interact
side
effect
narrow
therapeut
rang
necessit
monitor
drug
level
theophyllin
still
sometim
use
patient
demonstr
suffici
progress
otherwis
maxim
therapi
one
action
theophyllin
phosphodiesteras
pde
inhibitor
newer
select
pde
inhibitor
current
undergo
trial
see
chapter
data
support
use
intraven
albuterol
salbutamol
exacerb
copd
side
effect
common
inhal
rout
routin
use
recommend
although
exacerb
often
associ
increas
volum
tenac
sputum
firm
evid
current
support
use
mucolyt
drug
exacerb
copd
also
evid
support
strategi
facilit
expector
physiotherapi
salin
nebul
although
larg
reflect
absenc
evid
rather
evid
support
absenc
benefit
cough
suppress
contraind
central
respiratori
stimul
intraven
doxapram
larg
supersed
niv
therapi
clearli
patholog
pulmonari
embolu
achiev
adequ
oxygen
expens
rise
partial
pressur
co
arteri
blood
paco
fall
ph
indic
ventilatori
support
venturi
mask
provid
reliabl
fio
nasal
cannula
cannula
may
better
toler
noninvas
ventil
niv
refer
provis
ventilatori
support
use
nasal
fullfac
mask
patient
upper
airway
absenc
endotrach
tube
evid
support
use
niv
patient
hypercapn
respiratori
failur
caus
exacerb
copd
benefit
mortal
addit
reduct
hospit
stay
complic
may
larg
attribut
reduc
need
sedat
intub
invas
ventil
addit
contrast
invas
ventil
niv
may
use
earlier
intermitt
facilit
commun
nutrit
physiotherapi
niv
usual
administ
pressurecycl
bilevel
posit
airway
pressur
inspiratori
expiratori
pressur
may
independ
vari
howev
niv
substitut
invas
ventil
requir
therefor
manag
plan
consid
suitabl
invas
ventil
niv
fail
patient
may
rel
contraind
niv
respiratori
failur
sever
immedi
assess
invas
ventil
box
patient
suitabl
niv
abl
toler
treatment
figur
primari
indic
invas
ventil
exacerb
copd
sever
hypoxia
acidemia
ph
patient
unsuit
fail
niv
howev
although
data
suggest
patient
copd
similar
outcom
invas
ventil
patient
respiratori
failur
caus
decis
institut
invas
ventil
consid
patient
prior
function
statu
sever
current
underli
ill
degre
revers
present
deterior
presenc
sever
comorbid
mortal
follow
invas
ventil
wean
ventil
challeng
anoth
exacerb
hypercapn
respiratori
failur
paco
mm
hg
ph
sever
acidemia
lifethreaten
hypoxemia
inabl
protect
airway
hemodynam
instabl
inabl
clear
secret
undrain
pneumothorax
impair
conscious
agit
find
exacerb
suscept
vari
among
copd
patient
mean
particularli
import
target
exacerb
reduct
intervent
like
develop
event
simplest
way
ask
patient
mani
cours
system
antibiot
corticosteroid
therapi
receiv
exacerb
past
month
patient
receiv
two
cours
frequent
exacerb
like
remain
frequent
exacerb
futur
offer
appropri
exacerb
reduct
intervent
see
figur
therefor
varieti
measur
may
institut
reduc
number
consequ
exacerb
copd
patient
need
identifi
ask
prior
exacerb
histori
reason
assess
patient
present
respiratori
failur
usual
appropri
review
patient
ambulatori
care
set
admiss
acut
exacerb
research
exacerb
copd
move
rapidli
mani
year
ago
event
consid
noth
troublesom
deterior
symptom
without
longterm
consequ
know
true
mani
unansw
question
remain
still
understand
littl
bacteri
viral
pathogen
interact
effect
antiinflammatori
agent
requir
optim
role
antibiot
prevent
exacerb
remain
defin
current
effect
intervent
target
viral
pathogen
especi
rhinoviru
understand
patient
appear
suscept
exacerb
could
lead
develop
new
therapeut
approach
also
recogn
copd
associ
system
inflamm
may
caus
consider
cardiovascular
comorbid
way
assess
manag
may
reduc
number
impact
exacerb
patient
chronic
obstruct
pulmonari
diseas
superior
manag
hypercapn
respiratori
failur
remain
limit
role
doxapram
niv
appropri
bridg
niv
specialist
advic
conjunct
niv
use
doxapram
often
limit
sideeffect
especi
agit
potenti
benefit
appear
persist
beyond
hour
although
intraven
magnesium
may
effect
bronchodil
exacerb
asthma
convinc
data
avail
copd
routin
use
recommend
heliox
helium
oxygen
lower
viscos
air
may
therefor
reduc
work
breath
howev
remain
evid
benefit
exacerb
copd
support
measur
institut
includ
appropri
attent
fluid
balanc
consider
prophylaxi
venou
thromboembol
copd
patient
respond
maxim
therapi
escal
therapi
inappropri
rang
palli
approach
achiev
symptom
control
consid
use
analysi
symptom
lung
function
chang
median
length
exacerb
copd
patient
day
although
wide
variabl
proport
exacerb
take
consider
longer
patient
never
seem
recov
preexacerb
lung
function
patient
admit
inhospit
mortal
patient
hypercapn
respiratori
failur
mortal
approach
year
patient
may
suitabl
earli
support
discharg
associ
similar
outcom
appar
costeffect
standard
care
given
import
exacerb
manag
acut
event
import
consid
institut
rang
prevent
measur
reduc
risk
exacerb
copd
patient
mount
evid
suggest
number
drug
class
abl
reduc
exacerb
rate
includ
longact
agonist
laba
long
act
anticholinerg
inhal
corticosteroid
ic
least
moder
sever
underli
diseas
combin
therapi
laba
ic
appear
superior
use
either
alon
oral
corticosteroid
ineffect
prevent
exacerb
effect
outcom
measur
also
indic
stabl
copd
mucolyt
may
reduc
exacerb
frequenc
milder
diseas
take
ic
ongo
trial
reexamin
role
antibiot
reduc
exacerb
frequenc
evid
indic
antibiot
may
effect
mani
trial
includ
patient
simpl
chronic
bronchiti
also
drug
use
older
benefit
must
balanc
possibl
promot
drug
resist
macrolid
hold
particular
promis
given
recogn
antiinflammatori
action
vaccin
influenza
pneumococcu
pneumonia
recommend
underprescript
longterm
oxygen
therapi
requir
treatment
associ
hospit
readmiss
home
niv
therapi
may
reduc
admiss
chronic
hypercapn
respiratori
failur
although
specif
effect
reduc
exacerb
demonstr
pulmonari
rehabilit
also
shown
reduc
hospit
patient
copd
furthermor
earli
treatment
might
includ
patient
educ
program
reduc
exacerb
length
